H-RLQGISPKI-OH
Ref. 3D-PP43152
| 1mg | 217.00 € | ||
| 10mg | 253.00 € | ||
| 100mg | 455.00 € |
Product Information
- NH2-Arg-Leu-Gln-Gly-Ile-Ser-Pro-Lys-Ile-OH
Peptide H-RLQGISPKI-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-RLQGISPKI-OH include the following: SSX: Understanding an Antigen for Therapy in Prostate Cancer JE Bloom - 2017 - asset.library.wisc.eduhttps://asset.library.wisc.edu/1711.dl/GNWD26XUXSBD59D/R/file-9e24d.pdf Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells HA Smith , DG McNeel - Journal of Immunotherapy, 2011 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/fulltext/2011/10000/Vaccines_Targeting_the_Cancer_testis_Antigen_SSX_2.1.aspx Abstract# 4185: Identification of HLA-A2-restricted SSX-2 epitopes for the immunotherapy of prostate cancer H Smith , D McNeel - Cancer Research, 2009 - AACRhttps://aacrjournals.org/cancerres/article-abstract/69/9_Supplement/4185/556580 Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8+ T Cells CD Zahm , VT Colluru , DG McNeel - Cancer immunology research, 2017 - AACRhttps://aacrjournals.org/cancerimmunolres/article-abstract/5/8/630/468807 PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy CD Zahm , JE Moseman , LE Delmastro - , 2021 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1080/2162402X.2021.1912892
Chemical properties
Technical inquiry about: 3D-PP43152 H-RLQGISPKI-OH
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
